Observational studyJMIR public health and surveillance2026
Trends in Antimicrobial Consumption in Pakistan (2016-2028): Retrospective Observational Study With Forecasting.
Observational study in JMIR public health and surveillance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance is a public health crisis exacerbated by the irrational use of antibiotics, particularly in low- and middle-income countries. Pakistan, one of the highest consumers of antibiotics globally, faces unique challenges, including unregulated sales, overuse of broad-spectrum antibiotics, and inadequate stewardship programs. Objective: This study aimed to analyze antibiotic consumption trends in Pakistan from 2016 to 2023, project future use through 2028, and evaluate the subsequent implications for antimicrobial resistance and antimicrobial stewardship programs. Methods: Antibiotic sales data were retrieved for Pakistan from the IQVIA MIDAS database spanning 2016 to 2023. Data were converted to defined daily doses (DDDs) and DDD per 1000 inhabitants per day (DID) using the World Health Organization Anatomical Therapeutic Chemical classification system. Data cleaning, statistical analyses, and data visualization were performed using R software (version 4.3.2) and Microsoft Excel. Trends were analyzed using linear regression, while future projections (2024-2028) were developed using trend-based models. Descriptive analysis was performed, and visualizations were used to illustrate findings. Results: The total antibiotic consumption in Pakistan from 2016 to 2023 was 12.88 billion DDDs. Broad-spectrum penicillins and fluoroquinolones, each accounting for 37.7 DID, were the most consumed classes. The analysis revealed significant increases in the consumption of macrolides (+76%; rising from 2.26 to 3.99 DID) and cephalosporins (+36%; from 2.87 to 3.89 DID) from 2016 to 2023, with macrolides projected to reach 5.79 DID by 2028. Reserve antibiotics, including oxazolidinones (+354%; from 0.03-to 0.014 DID) and glycylcycline (+236%; from 0.001 to 0.0003 DID), also showed appreciable increases, reflecting greater reliance on last-line therapies. In contrast, aminoglycosides (-36%; from 0.013 to 0.14 DID) and narrow-spectrum penicillins (-30%; from 0.008 to 0.005 DID) experienced notable declines. Conclusions: The study highlights a concerning overreliance on broad-spectrum and reserve antibiotics in Pakistan, thus underscoring the urgent need for robust antimicrobial stewardship programs and stricter regulation of over-the-counter antibiotic sales to rationalize antibiotic use. Future efforts should focus on addressing gaps in prescribing practices, improving diagnostic capacity, and monitoring stewardship program outcomes to mitigate resistance development and preserve antibiotic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.